450 related articles for article (PubMed ID: 2157554)
1. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
[TBL] [Abstract][Full Text] [Related]
2. Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
Crinò L; Clerici M; Figoli F; Barduagni M; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F
Lung Cancer; 1995 Apr; 12 Suppl 1():S125-32. PubMed ID: 7551920
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.
Crinó L; Darwish S; Corgna E; Meacci ML; Di Costanzo F; Buzzi F; Fornari G; Santi F; Ballatori E; Luccioli L
Semin Oncol; 1988 Dec; 15(6 Suppl 7):52-5. PubMed ID: 2851180
[TBL] [Abstract][Full Text] [Related]
4. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer.
Crinò L; Latini P; Meacci M; Corgna E; Maranzano E; Darwish S; Minotti V; Santucci A; Tonato M
Ann Oncol; 1993 Dec; 4(10):847-51. PubMed ID: 8117604
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
Ali MA; Kraut MJ; Valdivieso M; Wozniak AJ; Cummings G; Kalemkerian GP
Cancer Invest; 2000; 18(1):1-5. PubMed ID: 10701360
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
9. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma.
Kawahara M; Furuse K; Kodama N; Yamamoto M; Kubota K; Takada M; Negoro S; Kusunoki Y; Matui K; Takifuji N
Cancer; 1991 Aug; 68(4):714-9. PubMed ID: 1649683
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
Pérol M; Guérin JC; Thomas P; Poirier R; Carles P; Robinet G; Kleisbauer JP; Paillotin D; Vergnenègre A; Balmes P; Touron D; Grivaux M; Pham E
Lung Cancer; 1996 Feb; 14(1):119-34. PubMed ID: 8696715
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
Comella P; Frasci G; Panza N; Manzione L; Lorusso V; Di Rienzo G; Cioffi R; De Cataldis G; Maiorino L; Bilancia D; Nicolella G; Natale M; Carpagnano F; Pacilio C; De Lena M; Bianco A; Comella G
J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
Luedke DW; Einhorn L; Omura GA; Sarma PR; Bartolucci AA; Birch R; Greco FA
J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054
[TBL] [Abstract][Full Text] [Related]
14. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.
Gandara DR; Perez EA; Wold H; Caggiano V; Malec M; Ahn DK; Meyers F; Carlson RW
Cancer Chemother Pharmacol; 1990; 27(3):243-7. PubMed ID: 2176134
[TBL] [Abstract][Full Text] [Related]
15. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
[TBL] [Abstract][Full Text] [Related]
16. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors.
Kodani T; Ueoka H; Kiura K; Tabata M; Takigawa N; Segawa Y; Moritaka T; Hiraki S; Harada M; Tanimoto M
Lung Cancer; 2002 Jun; 36(3):313-9. PubMed ID: 12009244
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
20. [Current results of chemotherapy in non-small cell lung cancer].
Fukuoka M; Negoro S; Takada M; Matsui K; Takifuji N; Masuda N; Kawahara M; Furuse K
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Feb; 28(2):203-9. PubMed ID: 2162439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]